Navigation Links
BioLineRx to Hold Analyst and Investor Day in New York on November 21, 2013
Date:11/5/2013

ed for breakthrough celiac treatments

The presentations will begin at 9:00 am EST and conclude at approximately 11:45 am EST. A recording of the presentations will be available after the event, through the Investor Relations section of BioLineRx's website, www.biolinerx.com, and at www.kcsa.com.

Analysts and qualified investors who would like to register or learn more about the event should contact Diane Imas of KCSA Strategic Communications at (212) 896-1242 or dimas@kcsa.com. Registration is required as space is limited.

About BioLineRx
BioLineRx is a publicly-traded biopharmaceutical development company dedicated to building a portfolio of products for unmet medical needs, as well as those with advantages over currently available therapies. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.

BioLineRx's current portfolio consists of a variety of clinical and pre-clinical projects, including: BL-1040 for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Ikaria Inc. and is in the midst of a pivotal CE-Mark registration trial; BL-5010 for non-surgical removal of skin lesions, which is expected to commence a pivotal CE-mark registration trial in late 2013; BL-8040 for treating acute myeloid leukemia (AML) and other hematological cancers, which is in the midst of a Phase 2 study; and BL-7010 for celiac disease, which is expected to commence a Phase 1/2 study in late 2013.

For more information on BioLineRx, please visit www.biolinerx.com
'/>"/>

SOURCE BioLineRx Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease
2. BioLineRx Announces In-Licensing of BL-9020, for Treatment of Type 1 Diabetes
3. BioLineRx Announces Regulatory Submission for Phase 1/2 Trial for Novel Treatment of Celiac Disease
4. BioLineRx Announces Receipt of a Notice of Allowance from USPTO for Patent on Use of BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C
5. BioLineRx To Present At 15th Annual Rodman & Renshaw Global Investment Conference In New York
6. BioLineRx Announces Issuance of United States Patent Covering Use of BL-8040 for Obtaining Stem Cells
7. BioLineRx to Present at 15th International Celiac Disease Symposium
8. BioLineRx to Present at 2013 Stifel Nicolaus Healthcare Conference In Boston
9. BioLineRx Appoints B. J. Bormann to Board of Directors
10. BioLineRx Reports Second Quarter 2013 Results
11. BioLineRx Announces Publication of Positive Pre-Clinical Results for BL-8040 in Treatment of Thrombocytopenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 ... has announced the addition of the "Investigation ... to their offering. Developed by Pharmacia ... prostaglandin receptor agonist which effectively reduces intraocular pressure. ... FDA, latanoprost (under the trade name of Xalatan) ...
(Date:8/28/2015)... Aug. 28, 2015 Perrigo Company plc ("Perrigo") ... Mylan N.V. ("Mylan") (NASDAQ: MYL ) shareholder vote ... "Our views of Mylan,s offer to Perrigo shareholders ... on our Board,s careful reflection of the value available ... limited choices that Mylan has allowed its shareholders to ...
(Date:8/28/2015)... , Joint research by Prof. Kim ... , Published in ,Stem Cells Translational Medicine, (IF ... multiple IV administration of Adipose-derived MSC , Increase ... , Commercialization within 5 years expected ... adult mesenchymal stem cells (MSCs) may extend healthy life ...
Breaking Medicine Technology:China Latanoprost Market Investigation Report 2015-2019 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2
(Date:8/28/2015)... Tempe, AZ (PRWEB) , ... August 29, 2015 , ... ... to reinvent higher learning and the student experience as part of the EDUCAUSE - ... Melinda Gates Foundation . , This is the third Breakthrough Models Incubator ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... An ... that local pizza maker Paul LaRocco has gone through to open a pizzeria in ... and permitting process tends to take several months, but the current process, having already ...
(Date:8/28/2015)... MA (PRWEB) , ... August 28, 2015 , ... The ... benefitting the renowned Brain Aneurysm Foundation has added yet another accolade to its cadre ... Rahm Emanuel. , “With the help of the medical community and the ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... Library for documenting and diagramming network and data center assets and audio-video devices, ... Device Model, Cisco Nexus 5000 Series, HP ProLiant Gen9, EMC VNX Series , ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... Dr. Gregory ... such as radiating pain resulting in shoulder pain, hip pain, neck pain, ... in Civil Engineering from the University of Illinois, and then went on to earn ...
Breaking Medicine News(10 mins):Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 2Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 3Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 3
... Oct. 29 Irvine Pharmaceutical Services,Inc., announced today that ... current and future industry demands, the company has promoted ... and added,to its staff Chief Operating Officer Greg McParland. ... growth as it gears up to launch its new,subsidiary, ...
... 29 Nu Skin Enterprises,Inc. (NYSE: NUS ... the,quarter of $310.3 million, a 7 percent improvement ... a 26 percent improvement over the,same quarter of ... 2,percent by foreign currency fluctuations and earnings per ...
... acquire US rights in tesamorelin, a Phase III compound ... HIV patients with lipodystrophy -- ... royalties on net sales in the US -- Merck KGaA, ... make equity investment in Theratechnologies -- EMD ...
... Use IPL to Clear Acne Blemishes, COSTA ... the CLARO acne-clearing device received marketing clearance by,the ... of mild to moderate,inflammatory acne. CLARO, the first ... treatment of acne, will be available by prescription,January ...
... of crafting smiles for Californians, Ron Greenspan, DDS, has been selected for ... the Washington, D.C. based U.S. Local Business Association (USLBA). , ... San ... smiles for Californians, Ron Greenspan, DDS, has been selected for the 2008 ...
... and increasing concerns for oral hygiene are considered the main factors contributing ... projected to reach $12.7 billion by the year 2012. , ... San ... one of the most dynamic segments of the oral care market. The ...
Cached Medicine News:Health News:Irvine Pharmaceutical Services Enhances Staff, Prepares for Innovative Expansion 2Health News:Nu Skin Enterprises Reports Third-Quarter 2008 Results 2Health News:Nu Skin Enterprises Reports Third-Quarter 2008 Results 3Health News:Nu Skin Enterprises Reports Third-Quarter 2008 Results 4Health News:Nu Skin Enterprises Reports Third-Quarter 2008 Results 5Health News:Nu Skin Enterprises Reports Third-Quarter 2008 Results 6Health News:Nu Skin Enterprises Reports Third-Quarter 2008 Results 7Health News:Nu Skin Enterprises Reports Third-Quarter 2008 Results 8Health News:Nu Skin Enterprises Reports Third-Quarter 2008 Results 9Health News:Nu Skin Enterprises Reports Third-Quarter 2008 Results 10Health News:Nu Skin Enterprises Reports Third-Quarter 2008 Results 11Health News:EMD Serono and Theratechnologies Announce Collaboration and Licensing Agreement for Tesamorelin in the United States 2Health News:EMD Serono and Theratechnologies Announce Collaboration and Licensing Agreement for Tesamorelin in the United States 3Health News:EMD Serono and Theratechnologies Announce Collaboration and Licensing Agreement for Tesamorelin in the United States 4Health News:EMD Serono and Theratechnologies Announce Collaboration and Licensing Agreement for Tesamorelin in the United States 5Health News:CLARO Receives FDA-Clearance for Treatment of Acne 2Health News:Dr. Ron Greenspan has Been Selected for the 2008 Best of San Diego Award in the Orthodontists Category by the U.S. Local Business Association 2Health News:Dr. Ron Greenspan has Been Selected for the 2008 Best of San Diego Award in the Orthodontists Category by the U.S. Local Business Association 3Health News:Global Toothpaste Market to Reach $12.7 Billion by 2012, According to a New Report by Global Industry Analysts, Inc. 2Health News:Global Toothpaste Market to Reach $12.7 Billion by 2012, According to a New Report by Global Industry Analysts, Inc. 3
... III DLE (Drug List Editor) Multi-Channel Infusion ... infusion technology. The instrument combines three independent ... versatility in an unparalleled small size. Now ... III Infusion System simplifies the delivery of ...
... The Gemini Family of infusion ... with a collective series of ... product line offers a wide ... IV sets, each featuring the ...
... first steps any hospital or health system ... powerful, most effective tools available for physicians ... clinician documentation and electronic medical record (EMR) ... this goal. In fact, its the most ...
... specialty Eraser instruments have been designed ... the right tool for situations requiring ... series of 25 gauge intraocular, bipolar, ... treatment of target tissues for fine-tip ...
Medicine Products: